FDA Awaits Word On Commissioner McClellan; Is He Headed To CMS?
This article was originally published in The Tan Sheet
Executive Summary
The public speculation about FDA Commissioner McClellan's next move within the Bush Administration indicates the importance of the Medicare prescription drug bill to the White House heading into the November elections
You may also be interested in...
CDER Deputy Galson Will Run Drug Center For At Least Six Months
Center for Drug Evaluation & Research Deputy Director Steve Galson, MD, will be acting center director during the period when FDA is expected to announce a decision on forced Rx-to-OTC switches
HHS Puts Stamp On FDA: Crawford Named Acting Commissioner
The appointment of former Virginia Tech Center for Food & Nutrition Policy head Lester Crawford, PhD/DVM, as acting commissioner puts FDA in the hands of HHS Secretary Tommy Thompson's preferred choice to lead the agency
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC